

Form PTO-1449 (Modified)	Atty. Docket No. 30754/39959	Serial No. 10/823,906
	Applicant(s) David E. Clarke	
	Filing Date April 14, 2004	Art Unit 1614

# INFORMATION DISCLOSURE STATEMENT



## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)
A1 /CH/	3,598,122	8/10/1971	Zaffaroni	204	607	
A2 /CH/	4,788,189	11/29/1988	Glazer	514	221	
A3 /CH/	4,965,074	10/23/1990	Leeson	424	449	
A4 /CH/	4,971,079	11/20/1990	Talapin	131	159	
A5 /CH/	5,016,652	5/21/1991	Rose et al.	131	270	
A6 /CH/	5,227,391	7/13/1993	Caldwell	514	343	
A7 /CH/	5,272,155	12/21/1993	Arneric et al.	514	315	
A8 /CH/	5,342,623	8/30/1994	Ensore et al.	424	448	
A9 /CH/	5,635,203	6/30/1997	Gale et al.	424	448	
A10 /CH/	5,780,051	7/14/1998	Eswara et al.	424	449	
A11 /CH/	5,977,131	11/02/1999	Nagel	514	300	
A12 /CH/	6,004,970	12/21/1999	O'Malley et al.	514	282	
A13 /CH/	6,280,761	8/28/2001	Santus	424	435	
A14 /CH/	6,280,763	8/28/2001	Midha et al.	424	448	
A15 /CH/	6,344,222	2/05/2002	Cherukuri et al.	426	6	
A16 /CH/	6,495,605	12/17/2002	McCullough et al.	514	646	
A17 /CH/	6,582,737	6/24/2003	Hirsh et al.	424	751	
A18 /CH/	6,596,740	7/22/2003	Jones	514	343	
A19 /CH/	6,620,428	9/16/2003	Hoeck et al.	424	449	
A20 /CH/	6,630,467	10/07/2003	O'Neill	514	233.2	
A21 /CH/	6,677,379	1/13/2004	Sikorski	514	649	
A22 /CH/	6,699,497	3/02/2004	van Osdol et al.	424	448	

EXAMINER: /Carlic Huynh/	DATE CONSIDERED: 08/21/2007
--------------------------	-----------------------------

Form PTO-1449 (Modified)	Atty. Docket No. 30754/39959	Serial No. 10/823,906
<b>INFORMATION DISCLOSURE STATEMENT</b>	Applicant(s) David E. Clarke	
	Filing Date April 14, 2004	Art Unit 1614

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes      No	

### OTHER DOCUMENTS

C1 /CH/	ALLGAYER, Hubert, <i>Gastrointestinal Pharmacology</i> , Sulfasalazine and 5-ASA Compounds, 21:643-658, 1992.
C2 /CH/	FREE et al., <i>Brain Research</i> , Surface and Intracellular Nicotinic Receptors Expressed in Intact Adrenal Chromaffin Cells: Direct Measurements Using [3H]epibatidine; 974:60-9, 2003.
C3 /CH/	GUSLANDI, M., <i>International Journal of Colorectal Disease</i> , Long-Term Effects of a Single Course of nicotine Treatment in Acute Ulcerative Colitis: Remission Maintenance in a 12-Month Follow-Up Study, 14:361-262, 1999.
C4 /CH/	IOANNIDES et al., <i>New England Journal of Medicine</i> , Rectal Administration of Metronidazole Provides Therapeutic Plasma Levels in Postoperative Patients, 305:1569-70, 1981.
C5 /CH/	Japanese Pharmacology & Therapeutics, 22:93-121 (1994).
C6 /CH/	KAWASHIMA et al., <i>Life Sciences</i> , The Lymphocytic Cholinergic System and its Biological Functions, 72:2101-9, 2003.
C7 /CH/	LASHNER et al., <i>Digestive Diseases and Sciences</i> , Testing Nicotine Gum for Ulcerative Colitis Patients, 35:827-32, 1990.
C7 /CH/	LI et al., <i>Current Gastroenterology Reports</i> , Assessing Disease Activity and Disease Activity Indices for Inflammatory Bowel Disease, 4:490-96, 2002.
C9 /CH/	LICHTIGER et al., <i>New England Journal of Medicine</i> , Cyclosporine in Sever Ulcerative Colitis Refractory to Steroid Therapy, 330:1841-1845, 1994.
C10 /CH/	MELGAR et al., <i>Clinical and Experimental Immunology</i> , Over-Expression of Interleukin 10 in Mucosal T Cells of Patients with Active Ulcerative Colitis, 134:127-37, 2003
C11 /CH/	RACHMILEWITZ, D., <i>British Medical Journal</i> , Coated Mesalazine (5-aminosalicylic acid) Versus Sulphasalazine in the Treatment of Active Ulcerative Colitis: A Randomised Trial, 298:82-82, 1989.
C12 /CH/	ROBINSON et al., <i>Journal of Laboratory and Clinical Medicine</i> , Regulation of Neutrophils in Ulcerative Colitis by Colonic Factors: A Possible Mechanism of Neutrophil Activation and Tissue Damage, 130:590-602, 1997.
C13 /CH/	SANDBORN, W., <i>American Journal of Gastroenterology</i> , Nicotine Therapy for Ulcerative colitis: A Review of Rationale, Mechanisms, Pharmacology and Clinical Results, 94:1161-1171, 1999.

EXAMINER: /Carlic Huynh/	DATE CONSIDERED: 08/21/2007
--------------------------	-----------------------------

Form PTO-1449 (Modified)  <b>INFORMATION DISCLOSURE STATEMENT</b>	Atty. Docket No. 30754/39959	Serial No. 10/823,906
	Applicant(s) David E. Clarke	
	Filing Date April 14, 2004	Art Unit 1614

C14	/CH/	SINGH, PARMINDER et al., "Iontophoresis in Drug Delivery: Basic Principles and Applications", <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 11:161-213, 1994.
C15	/CH/	Sogo Rinsho (Comprehensive Clinic), 43:1725-1729 (1994).
C16	/CH/	TAMBOLI et al., <i>Best Practice and Research Clinical Gastroenterology</i> , Probiotics in Inflammatory Bowel Disease: A Critical Review, 17:805-20, 2003.
C17	/CH/	TANG et al., <i>Cellular Signalling</i> , CaM Kinase II-Dependent Phosphorylation of Myogenin Contributes to Activity-Dependent Suppression of nAChR Gene Expression in Developing Rat Myotubes, 16:551-63, 2004.
C18	/CH/	THOMAS et al., <i>New England Journal of Medicine</i> , Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis, 332:988-92, 1995.
C19	/CH/	The Merck Manual, Seventeenth Edition, p. 309, 1999.
C20	/CH/	WICK, Steven, "Developing a Drug-In-Adhesive Design for Transdermal Drug Delivery", <i>Adhesives Age</i> , 38(10):18-24, 1995.

EXAMINER: /Carlic Huynh/	DATE CONSIDERED: 08/21/2007
--------------------------	-----------------------------